Intranasal delivery of rotigotine to the brain for treating Parkinson’s disease

IF 6.3 3区综合性期刊 Q1 Multidisciplinary

Fundamental Research Pub Date : 2025-09-01 DOI:10.1016/j.fmre.2025.02.004

Dandan Kou , Keyang Xu , Jiahui Yin , Ning Wang , Ruru Zhang , Jianfeng Zeng , Mingyuan Gao

{"title":"Intranasal delivery of rotigotine to the brain for treating Parkinson’s disease","authors":"Dandan Kou , Keyang Xu , Jiahui Yin , Ning Wang , Ruru Zhang , Jianfeng Zeng , Mingyuan Gao","doi":"10.1016/j.fmre.2025.02.004","DOIUrl":null,"url":null,"abstract":"<div><div>The development of sustainable and non-invasive method for delivering drugs to the brain is crucial for the effective treatment of Parkinson’s disease (PD). In this study, nanoparticles were formulated by using poly (ethylene glycol)-block-poly (propylene glycol)-block-poly (ethylene glycol) (PEG-<em>b</em>-PPG-<em>b</em>-PEG) to facilitate an efficient intranasal delivery of rotigotine directly into the brain. It was found that the intranasal route enabled more effective accumulation of rotigotine in the brain than conventional intravenous administration, demonstrating its feasibility as an innovative delivery approach for PD treatment. Furthermore, the behavioral test, brain histology and immunochemistry analyses demonstrated a significant improvement in the symptoms of PD-like neurodegeneration in mice treated with intranasally delivered rotigotine-loaded nanoparticles. These outcomes affirm an outstanding therapeutic efficacy of the nano-formulation for intranasal delivery, highlighting its potential for the effective treatment of neurodegenerative disorders, particularly PD.</div></div>","PeriodicalId":34602,"journal":{"name":"Fundamental Research","volume":"5 5","pages":"Pages 1911-1919"},"PeriodicalIF":6.3000,"publicationDate":"2025-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Fundamental Research","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2667325825000871","RegionNum":3,"RegionCategory":"综合性期刊","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"Multidisciplinary","Score":null,"Total":0}

引用次数: 0

Abstract

The development of sustainable and non-invasive method for delivering drugs to the brain is crucial for the effective treatment of Parkinson’s disease (PD). In this study, nanoparticles were formulated by using poly (ethylene glycol)-block-poly (propylene glycol)-block-poly (ethylene glycol) (PEG-b-PPG-b-PEG) to facilitate an efficient intranasal delivery of rotigotine directly into the brain. It was found that the intranasal route enabled more effective accumulation of rotigotine in the brain than conventional intravenous administration, demonstrating its feasibility as an innovative delivery approach for PD treatment. Furthermore, the behavioral test, brain histology and immunochemistry analyses demonstrated a significant improvement in the symptoms of PD-like neurodegeneration in mice treated with intranasally delivered rotigotine-loaded nanoparticles. These outcomes affirm an outstanding therapeutic efficacy of the nano-formulation for intranasal delivery, highlighting its potential for the effective treatment of neurodegenerative disorders, particularly PD.

Abstract Image

查看原文本刊更多论文

罗替戈汀鼻内入脑治疗帕金森病

开发一种可持续的、无创的给药方法是有效治疗帕金森病的关键。在这项研究中，纳米颗粒由聚（乙二醇）-块状聚（丙二醇）-块状聚（乙二醇）（PEG-b-PPG-b-PEG）配制而成，以促进罗替戈汀有效的鼻内直接进入大脑。研究发现，与传统静脉给药相比，鼻内给药能更有效地在大脑中积累罗替戈汀，这证明了其作为PD治疗的一种创新给药方法的可行性。此外，行为测试、脑组织组织学和免疫化学分析表明，经鼻给药罗替戈汀纳米颗粒治疗的小鼠pd样神经变性症状有显著改善。这些结果证实了鼻内给药纳米制剂的卓越治疗效果，突出了其有效治疗神经退行性疾病，特别是PD的潜力。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊